Relay Therapeutics (RLAY) Shares Climb After FDA Grants Breakthrough Status to Zovegalisib

CAMBRIDGE, MA — Shares of Relay Therapeutics Inc (NASDAQ: RLAY) saw a notable 3.8% jump in premarket trading on Tuesday. The rally follows the company’s announcement that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its lead oncology candidate, zovegalisib, in combination with fulvestrant.

Expedited Path for High-Need Breast Cancer Treatment

The FDA’s designation specifically targets adults with PIK3CA mutant, HR+/HER2- locally advanced or metastatic breast cancer. This patient population often faces limited options after their disease progresses following initial treatment with CDK4/6 inhibitors.

Why it Matters: Breakthrough Therapy status is a regulatory catalyst designed to accelerate the development and review of drugs for serious conditions. For Relay Therapeutics, this means increased engagement with senior FDA leadership and frequent guidance to bring the drug to market faster.

Clinical Momentum: The ReDiscover Trial

The FDA’s decision was underpinned by promising clinical data from Relay’s Phase 1/2 ReDiscover trial. Key highlights include:

• Target Mutation: Approximately 40% of patients with this specific form of advanced breast cancer harbor PIK3CA mutations.

• Dosing Strategy: The application utilized data from the 400mg BID fed dose, which is currently being utilized in the ongoing Phase 3 ReDiscover-2 trial.

What’s Next for Investors?

Relay Therapeutics is scheduled to present initial Phase 1/2 data at the ESMO Targeted Anticancer Therapies Congress on March 16. Investors will be looking for efficacy benchmarks that could solidify zovegalisib’s position as a potential new standard of care in the $15+ billion breast cancer therapy market.